PL3544634T3 - Koniugaty przeciwciało MET-lek - Google Patents

Koniugaty przeciwciało MET-lek

Info

Publication number
PL3544634T3
PL3544634T3 PL17817374T PL17817374T PL3544634T3 PL 3544634 T3 PL3544634 T3 PL 3544634T3 PL 17817374 T PL17817374 T PL 17817374T PL 17817374 T PL17817374 T PL 17817374T PL 3544634 T3 PL3544634 T3 PL 3544634T3
Authority
PL
Poland
Prior art keywords
drug conjugates
antibody drug
met antibody
met
conjugates
Prior art date
Application number
PL17817374T
Other languages
English (en)
Inventor
Yiqing Feng
Philip Arthur Hipskind
Renhua Li
Ling Liu
Takako Wilson
Aaron David WROBLESKI
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL3544634T3 publication Critical patent/PL3544634T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17817374T 2016-11-23 2017-11-17 Koniugaty przeciwciało MET-lek PL3544634T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662425853P 2016-11-23 2016-11-23
PCT/US2017/062247 WO2018098035A1 (en) 2016-11-23 2017-11-17 Met antibody drug conjugates
EP17817374.6A EP3544634B1 (en) 2016-11-23 2017-11-17 Met antibody drug conjugates

Publications (1)

Publication Number Publication Date
PL3544634T3 true PL3544634T3 (pl) 2021-09-27

Family

ID=60703003

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17817374T PL3544634T3 (pl) 2016-11-23 2017-11-17 Koniugaty przeciwciało MET-lek

Country Status (15)

Country Link
US (1) US11167039B2 (pl)
EP (1) EP3544634B1 (pl)
JP (1) JP6951441B2 (pl)
CN (1) CN110022903B (pl)
CY (1) CY1124266T1 (pl)
DK (1) DK3544634T3 (pl)
ES (1) ES2875365T3 (pl)
HR (1) HRP20210922T1 (pl)
HU (1) HUE054500T2 (pl)
LT (1) LT3544634T (pl)
PL (1) PL3544634T3 (pl)
PT (1) PT3544634T (pl)
RS (1) RS61967B1 (pl)
SI (1) SI3544634T1 (pl)
WO (1) WO2018098035A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
SG11202108525VA (en) * 2019-02-21 2021-09-29 Regeneron Pharma Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
KR20230018454A (ko) * 2020-09-01 2023-02-07 레메젠 코, 리미티드 항-c-Met 항체-약물 접합체 및 이의 용도
AU2022218165B2 (en) 2021-02-03 2024-02-29 Mythic Therapeutics, Inc. Anti-met antibodies and uses thereof
EP4320152A1 (en) * 2021-04-08 2024-02-14 Byondis B.V. Anti-c-met antibodies and antibody-drug conjugates
TW202434307A (zh) 2023-01-18 2024-09-01 大陸商泰勵生物科技（上海）有限公司 抗體偶聯藥物及其用途
WO2025078841A2 (en) 2023-10-11 2025-04-17 Antikor Biopharma Limited Antibodies, conjugates, and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
DK1912671T3 (da) * 2005-07-18 2017-11-27 Seattle Genetics Inc Beta-glucuronid-linker-lægemiddelkonjugater
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
SMT201900500T1 (it) 2011-05-08 2019-11-13 Legochem Biosciences Inc Coniugati di agente protettivo-proteina e metodo per preparare i medesimi
EA201791203A1 (ru) 2014-12-08 2018-04-30 Сорренто Терапьютикс, Инк. ЛЕКАРСТВЕННЫЙ КОНЪЮГАТ АНТИТЕЛА ПРОТИВ с-МЕТ
CN114177308B (zh) * 2016-05-17 2024-07-09 艾伯维生物制药股份有限公司 抗cMet抗体药物偶联物及其使用方法

Also Published As

Publication number Publication date
JP6951441B2 (ja) 2021-10-20
WO2018098035A1 (en) 2018-05-31
DK3544634T3 (da) 2021-06-07
LT3544634T (lt) 2021-06-10
CN110022903B (zh) 2022-06-03
ES2875365T3 (es) 2021-11-10
PT3544634T (pt) 2021-06-02
CN110022903A (zh) 2019-07-16
HUE054500T2 (hu) 2021-09-28
EP3544634B1 (en) 2021-04-14
US20200061204A1 (en) 2020-02-27
CY1124266T1 (el) 2022-07-22
HRP20210922T1 (hr) 2021-09-03
US11167039B2 (en) 2021-11-09
RS61967B1 (sr) 2021-07-30
EP3544634A1 (en) 2019-10-02
SI3544634T1 (sl) 2021-08-31
JP2019536780A (ja) 2019-12-19

Similar Documents

Publication Publication Date Title
IL291073A (en) Drug conjugates of anti-egfr antibodies
IL290457A (en) Antibodies and their conjugates
IL267003A (en) Multidrug antibody conjugates
IL265309A (en) Bispecific antibodies against MUC16 and CD3 and drug conjugates against MUC16
IL267834B1 (en) Conjugates of drug and antibody against ccr7
IL252015A0 (en) Antibody drug conjugates
IL263600A (en) Antibodies against b7-h3 and conjugates of drug and antibody
IL250189A0 (en) Anti–cdh6 antibody drug conjugates
IL251938A0 (en) Antibodies against CS1 and antibody-drug conjugates
SG10202002153PA (en) Glycoengineered antibody drug conjugates
IL274650A (en) Conjugate an antibody drug against CD40
EP3253212A4 (en) Antibody drug conjugates
EP3250238A4 (en) Antibody drug conjugates
IL259651A (en) Conjugations between an antibody to a specific her2 site and a drug
LT3137114T (lt) Anti-ptk7 antikūnų ir vaistų konjugatai
ZA202004675B (en) Pharmaceutical combinations comprising an anti-ly75 antibody
PT3544634T (pt) Conjugados anticorpo-fármaco anti-met
EP3180388A4 (en) Polyoxazoline antibody drug conjugates
LU92659B1 (en) Glycooptimized antibody drug conjugates
HK1239709A1 (en) Antibody drug conjugates
HK1233662A1 (en) Anti-cdh6 antibody drug conjugates